

Blood Sciences Laboratory
5th Floor North Wing
St Thomas' Hospital
London SE1 7EH

28th June 2023

Dear Colleagues,

RE: Dual reporting of tumour markers - update

As you are aware the biochemistry analytical service at St Thomas' Hospital and Guy's Hospital sites went live with new Abbott Alinity analysers on the 17th November 2022. Since then we have been parallel reporting **cancer antigen 125 (CA-125), carbohydrate antigen 19-9 (CA-199) and neuron-specific enolase (NSE)** results (i.e. running both the old (Roche) and new (Abbott) methods and reporting results simultaneously). This was to allow for a familiarisation phase of at least 6 months.

We are writing to inform you that we will **no longer be dual reporting the following tumour markers: CA-125, CA19-9 and NSE as of the 1st July 2023**. Results will only be available and reported using the Abbott Alinity analysers.

We will continue to dual report **human chorionic gonadotropin (HCG)**.

Should you have any questions regarding this change or should you require any clinical advice concerning these tumour markers, please contact us using the details below.

Yours sincerely



Dr Sunita Sardiwal,
Consultant Clinical Scientist
Sunita.Sardiwal@gstt.nhs.uk

Professor Anthony Wierzbicki,
Consultant Chemical Pathologist
Tony.Wierzbicki@gstt.nhs.uk



Darren Costello,
Director of Operations
Blood Sciences Division Synnovis
Darren.Costello@synnovis.co.uk